IL304471A - Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases - Google Patents
Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseasesInfo
- Publication number
- IL304471A IL304471A IL304471A IL30447123A IL304471A IL 304471 A IL304471 A IL 304471A IL 304471 A IL304471 A IL 304471A IL 30447123 A IL30447123 A IL 30447123A IL 304471 A IL304471 A IL 304471A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- type
- cell proliferation
- small molecule
- lung diseases
- Prior art date
Links
- 208000019693 Lung disease Diseases 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163139956P | 2021-01-21 | 2021-01-21 | |
| PCT/US2022/070259 WO2022159955A1 (en) | 2021-01-21 | 2022-01-20 | Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304471A true IL304471A (en) | 2023-09-01 |
Family
ID=80446393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304471A IL304471A (en) | 2021-01-21 | 2023-07-13 | Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240174675A1 (https=) |
| EP (1) | EP4281439A1 (https=) |
| JP (1) | JP2024504328A (https=) |
| KR (1) | KR20230135625A (https=) |
| CN (1) | CN117177958A (https=) |
| AU (1) | AU2022211069A1 (https=) |
| CA (1) | CA3209219A1 (https=) |
| IL (1) | IL304471A (https=) |
| MX (1) | MX2023008275A (https=) |
| WO (1) | WO2022159955A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3261924A1 (en) * | 2022-07-14 | 2024-01-18 | The Scripps Research Institute | SMALL MOLECULE REGULATORS OF TYPE 2 ALVEOLAR CELL PROLIFERATION FOR THE TREATMENT OF LUNG DISEASES |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| WO2006012441A1 (en) * | 2004-07-23 | 2006-02-02 | Susan Marie Royalty | Peptidase inhibitors |
| WO2006090244A1 (en) * | 2005-02-22 | 2006-08-31 | Glenmark Pharmaceuticals S.A. | New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them |
| CN101468988A (zh) * | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| CN101824036A (zh) * | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
| CN101849944A (zh) * | 2009-03-31 | 2010-10-06 | 江苏恒瑞医药股份有限公司 | 治疗2型糖尿病的药物组合物 |
| CN103087067A (zh) * | 2012-08-02 | 2013-05-08 | 盛世泰科生物医药技术(苏州)有限公司 | 作为二肽基酶抑制剂的化合物及其组合物，以及它们的用途 |
| CN103896923B (zh) * | 2012-12-27 | 2016-03-02 | 北京莱博赛路森药物科技有限公司 | 一种降血糖化合物、其制备方法、包含其的药物组合物及其用途 |
| CN107303390A (zh) * | 2017-01-22 | 2017-10-31 | 复旦大学附属华山医院 | Dpp4抑制剂在制备治疗低氧性肺动脉高压药物中的用途 |
-
2022
- 2022-01-20 KR KR1020237028393A patent/KR20230135625A/ko active Pending
- 2022-01-20 JP JP2023543456A patent/JP2024504328A/ja active Pending
- 2022-01-20 MX MX2023008275A patent/MX2023008275A/es unknown
- 2022-01-20 CN CN202280015600.8A patent/CN117177958A/zh active Pending
- 2022-01-20 EP EP22704251.2A patent/EP4281439A1/en active Pending
- 2022-01-20 US US18/261,889 patent/US20240174675A1/en active Pending
- 2022-01-20 AU AU2022211069A patent/AU2022211069A1/en active Pending
- 2022-01-20 CA CA3209219A patent/CA3209219A1/en active Pending
- 2022-01-20 WO PCT/US2022/070259 patent/WO2022159955A1/en not_active Ceased
-
2023
- 2023-07-13 IL IL304471A patent/IL304471A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022211069A1 (en) | 2023-07-27 |
| WO2022159955A1 (en) | 2022-07-28 |
| KR20230135625A (ko) | 2023-09-25 |
| CA3209219A1 (en) | 2022-07-28 |
| JP2024504328A (ja) | 2024-01-31 |
| MX2023008275A (es) | 2023-07-19 |
| US20240174675A1 (en) | 2024-05-30 |
| CN117177958A (zh) | 2023-12-05 |
| EP4281439A1 (en) | 2023-11-29 |
| AU2022211069A9 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| IL284071A (en) | Amino-acid anilides as small molecule modulators of il-17 | |
| IL282140A (en) | Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy | |
| CL2019003793A1 (es) | Moduladores de moléculas pequeñas de sting humana. | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| EP4301141A4 (en) | Combination therapy for treatment of conditions associated with aging | |
| MX2018013002A (es) | Moduladores de la proteina reguladora de la conductancia transmembrana de la fibrosis quistica. | |
| CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
| EP4236831C0 (en) | BODY LIGHT THROMBUS TREATMENT SYSTEM | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| CL2018000622A1 (es) | Acetamida tienodiazepinas de triazol y sus usos relacionados. | |
| MX378806B (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas. | |
| MX2024005705A (es) | Composiciones de liquidos ionicos. | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| IL281244A (en) | Combination therapy for the treatment of liver disease | |
| LT3890767T (lt) | Inhaliuojamos kompozicijos, skirtos naudoti plaučių ligų gydymui | |
| EP3857635A4 (en) | CHEMICAL PRE-ALCALATION OF ELECTRODES | |
| IL281923A (en) | Compositions useful for treating gm1 gangliosidosis | |
| SI3990005T1 (sl) | Pegilirana cistationin beta-sintaza za encimsko terapijo za zdravljenjehomocistinurije | |
| EA201892264A1 (ru) | Производные тетрагидроизохинолина | |
| EP3927428C0 (en) | NORKETOTIFEN FOR THE TREATMENT OF RESPIRATORY DISORDERS | |
| EP4442710A4 (en) | Combination of drugs for the treatment of non-small cell lung cancer | |
| CR20210499A (es) | Compuestos y composiciones como moduladores de la señalización de tlr |